The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.

Autor: Vesikari T; Nordic Research Network Oy, Tampere, Finland., Langley JM; Canadian Center for Vaccinology (Dalhousie University, IWK and Nova Scotia Health), Canada., Spaans JN; VBI Vaccines Inc, Cambridge, MA, United States., Petrov I; VBI Vaccines Inc, Cambridge, MA, United States., Popovic V; VBI Vaccines Inc, Cambridge, MA, United States., Yassin-Rajkumar B; VBI Vaccines Inc, Cambridge, MA, United States., Anderson DE; VBI Vaccines Inc, Cambridge, MA, United States., Diaz-Mitoma F; VBI Vaccines Inc, Cambridge, MA, United States. Electronic address: fdiazmitoma@vbivaccines.com.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2023 Jun 01; Vol. 41 (24), pp. 3584-3588. Date of Electronic Publication: 2023 May 11.
DOI: 10.1016/j.vaccine.2023.05.010
Abstrakt: Prevention of hepatitis B virus (HBV) infection by vaccination can potentially eliminate HBV-related diseases. PreHevbrio™/PreHevbri® is a 3-antigen (S, preS1, preS2) HBV vaccine (3A-HBV) recently licensed for adults in the US, EU and Canada. This study evaluated antibody persistence in a subset of fully vaccinated and seroprotected (anti-HBs ≥ 10 mIU/mL) Finnish participants from the phase 3 trial (PROTECT) of 3A-HBV versus single-antigen HBV vaccine (1A-HBV). 465/528 eligible subjects were enrolled (3A-HBV: 244; 1A-HBV: 221). Baseline characteristics were balanced. After 2.5 years, more 3A-HBV subjects remained seroprotected (88.1 % [95 %CI: 84.1,92.2]) versus 1A-HBV (72.4 % [95 %CI: 66.6,78.3)], p < 0.0001) and had higher mean anti-HBs [1382.9 mIU/mL (95 %CI: 1013.8,1751.9) versus 252.6 mIU/mL (95 %CI: 127.5,377.6), p < 0.0001]. In multiple variable logistic regression analysis including age, vaccine, initial vaccine response, sex and BMI, only higher post dose 3 (Day 196) antibody titers significantly reduced the odds of losing seroprotection.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Vesikari reported being the majority shareholder of Nordic Research Network Oy and to receiving grants from VBI Vaccines during the conduct of the study. Dr Popovic reported receiving personal fees from VBI Vaccines during the conduct of the study and outside the submitted work. Dr Diaz-Mitoma reported receiving personal fees from VBI Vaccines during the conduct of the study; owning shares in VBI Vaccines outside the submitted work. I. Petrov is an employee of VBI Vaccines. J. Spaans was a VBI Vaccines employee during the conduct of the study.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: